Lateral Flow Assay for Prostate Cancer Diagnosis
Description/Abstract/Artist Statement
Approximately 34,000 men in the United States lost their lives to prostate cancer (PCa) in 2021 according to the National Institutes of Health’s Cancer Institute. Making prostate cancer the second leading cause of death in American men. Prostate cancer diagnosis, often occurring in the later stages where survival rates are lower, is achieved with a core needle biopsy. This invasive procedure that tests for the prostate specific antigen, an antigen that when elevated is indicative of cancer, has a significant number of PCa false positives. Gold nanoparticles (AuNPs) selectivity and biocompatibility makes them ideal candidates for prostate cancer diagnosis. Here a lateral flow biosensor (LFB) assay is developed using AuNPs to diagnosis PCa. This LFB tests for oncogenic and tumor suppressor PCa-associated miRNAs. The developed LFB produced visual and numerical data to decrease the false positive rates in prostate cancer testing. This LFB has the potential to enable earlier diagnosis of prostate cancer and ultimately save lives.
Faculty Advisor/Mentor
Gymama Slaughter, Alexis Moody
College Affiliation
College of Sciences
Presentation Type
Poster
Disciplines
Biochemistry | Chemistry
Session Title
Poster Session
Location
Learning Commons @ Perry Library
Start Date
3-19-2022 9:00 AM
End Date
3-19-2022 11:00 AM
Lateral Flow Assay for Prostate Cancer Diagnosis
Learning Commons @ Perry Library
Approximately 34,000 men in the United States lost their lives to prostate cancer (PCa) in 2021 according to the National Institutes of Health’s Cancer Institute. Making prostate cancer the second leading cause of death in American men. Prostate cancer diagnosis, often occurring in the later stages where survival rates are lower, is achieved with a core needle biopsy. This invasive procedure that tests for the prostate specific antigen, an antigen that when elevated is indicative of cancer, has a significant number of PCa false positives. Gold nanoparticles (AuNPs) selectivity and biocompatibility makes them ideal candidates for prostate cancer diagnosis. Here a lateral flow biosensor (LFB) assay is developed using AuNPs to diagnosis PCa. This LFB tests for oncogenic and tumor suppressor PCa-associated miRNAs. The developed LFB produced visual and numerical data to decrease the false positive rates in prostate cancer testing. This LFB has the potential to enable earlier diagnosis of prostate cancer and ultimately save lives.